143 related articles for article (PubMed ID: 11856593)
41. EORTC/GTO adjuvant chemotherapy program for primary Ewing's sarcoma: results at 5 years.
Le Mevel BP; Hoerni B; Durant D; Kenesi C; Salle M; Trifaud A; Liegey-Bagari D; Bainvel JV; Rogez JM; Fumoleau P; Mazabraud A; Dumont J; Tomend B; Brossel E; Garetta M; Guerrin D; Jasmin C; Sancho-Garnier H; Gimenez M
Recent Results Cancer Res; 1978; 68():52-9. PubMed ID: 752883
[No Abstract] [Full Text] [Related]
42. The Ewing family of tumors. Ewing's sarcoma and primitive neuroectodermal tumors.
Grier HE
Pediatr Clin North Am; 1997 Aug; 44(4):991-1004. PubMed ID: 9286296
[TBL] [Abstract][Full Text] [Related]
43. Role of Radiotherapy in the Multimodal Treatment of Ewing Sarcoma Family Tumors.
Choi Y; Lim DH; Lee SH; Lyu CJ; Im JH; Lee YH; Suh CO
Cancer Res Treat; 2015 Oct; 47(4):904-12. PubMed ID: 25687849
[TBL] [Abstract][Full Text] [Related]
44. Ewing sarcoma: treatment with high dose radiation and adjuvant chemotherapy.
Graham-Pole J
Med Pediatr Oncol; 1979; 7(1):1-8. PubMed ID: 118328
[TBL] [Abstract][Full Text] [Related]
45. RT-PCR evaluation of peripheral blood, bone marrow and peripheral blood stem cells in children and adolescents undergoing VACIME chemotherapy for Ewing's sarcoma and alveolar rhabdomyosarcoma.
Thomson B; Hawkins D; Felgenhauer J; Radich J
Bone Marrow Transplant; 1999 Sep; 24(5):527-33. PubMed ID: 10482938
[TBL] [Abstract][Full Text] [Related]
46. Treatment of sarcomas of the chest wall using intensive combined modality therapy.
Young MM; Kinsella TJ; Miser JS; Triche TJ; Glaubiger DL; Steinberg SM; Glatstein E
Int J Radiat Oncol Biol Phys; 1989 Jan; 16(1):49-57. PubMed ID: 2643597
[TBL] [Abstract][Full Text] [Related]
47. Systemic therapy for osteosarcoma and Ewing sarcoma.
Meyers PA
Am Soc Clin Oncol Educ Book; 2015; ():e644-7. PubMed ID: 25993235
[TBL] [Abstract][Full Text] [Related]
48. No advantages in the addition of ifosfamide and VP-16 to the standard four-drug regimen in the maintenance phase of neoadjuvant chemotherapy of Ewing's sarcoma of bone: results of two sequential studies.
Bacci G; Picci P; Ruggieri P; Ferrari S; Mercuri M; Fabbri N; Rosito P; Barbieri E; Ferraro A; Casadei R
J Chemother; 1993 Aug; 5(4):247-57. PubMed ID: 8229153
[TBL] [Abstract][Full Text] [Related]
49. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
50. The role of radiotherapy in local control of nonextremity Ewing sarcomas.
Akagunduz OO; Kamer SA; Kececi B; Demirag B; Oniz H; Kantar M; Cetingul N; Sabah D; Anacak Y
Tumori; 2016; 102(2):162-7. PubMed ID: 26917407
[TBL] [Abstract][Full Text] [Related]
51. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma.
Burdach S; Jürgens H; Peters C; Nürnberger W; Mauz-Körholz C; Körholz D; Paulussen M; Pape H; Dilloo D; Koscielniak E
J Clin Oncol; 1993 Aug; 11(8):1482-8. PubMed ID: 8101562
[TBL] [Abstract][Full Text] [Related]
52. Adjuvant chemotherapy in Ewing's sarcoma patients.
Gasparini M; Lombardi F
Recent Results Cancer Res; 1982; 80():120-3. PubMed ID: 7036274
[TBL] [Abstract][Full Text] [Related]
53. Neoadjuvant chemotherapy for Ewing's sarcoma of bone: no benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase--results of two sequential studies.
Bacci G; Picci P; Ferrari S; Mercuri M; Brach del Prever A; Rosito P; Barbieri E; Tienghi A; Forni C
Cancer; 1998 Mar; 82(6):1174-83. PubMed ID: 9506366
[TBL] [Abstract][Full Text] [Related]
54. Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor-risk Ewing-Sarcoma-Family tumors.
Hawkins D; Barnett T; Bensinger W; Gooley T; Sanders J
Med Pediatr Oncol; 2000 May; 34(5):328-37. PubMed ID: 10797354
[TBL] [Abstract][Full Text] [Related]
55. Characterization and drug resistance patterns of Ewing's sarcoma family tumor cell lines.
May WA; Grigoryan RS; Keshelava N; Cabral DJ; Christensen LL; Jenabi J; Ji L; Triche TJ; Lawlor ER; Reynolds CP
PLoS One; 2013; 8(12):e80060. PubMed ID: 24312454
[TBL] [Abstract][Full Text] [Related]
56. Primary cutaneous and subcutaneous Ewing sarcoma.
Di Giannatale A; Frezza AM; Le Deley MC; Marec-Bérard P; Benson C; Blay JY; Bui B; Judson I; Oberlin O; Whelan J; Gaspar N
Pediatr Blood Cancer; 2015 Sep; 62(9):1555-61. PubMed ID: 25894676
[TBL] [Abstract][Full Text] [Related]
57. Effect of low-dose radiation therapy when combined with surgical resection for Ewing sarcoma.
Merchant TE; Kushner BH; Sheldon JM; LaQuaglia M; Healey JH
Med Pediatr Oncol; 1999 Aug; 33(2):65-70. PubMed ID: 10398178
[TBL] [Abstract][Full Text] [Related]
58. Growth rate investigation and tumor lethal dose in Ewing's sarcoma.
Pearlman AW
Acta Radiol Ther Phys Biol; 1973 Feb; 12(1):57-70. PubMed ID: 4725646
[No Abstract] [Full Text] [Related]
59. Long-term results from the first UKCCSG Ewing's Tumour Study (ET-1). United Kingdom Children's Cancer Study Group (UKCCSG) and the Medical Research Council Bone Sarcoma Working Party.
Craft AW; Cotterill SJ; Bullimore JA; Pearson D
Eur J Cancer; 1997 Jun; 33(7):1061-9. PubMed ID: 9376188
[TBL] [Abstract][Full Text] [Related]
60. Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group.
Foulon S; Brennan B; Gaspar N; Dirksen U; Jeys L; Cassoni A; Claude L; Seddon B; Marec-Berard P; Whelan J; Paulussen M; Streitbuerger A; Oberlin O; Juergens H; Grimer R; Le Deley MC
Eur J Cancer; 2016 Jul; 61():128-36. PubMed ID: 27176931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
